Repligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements
December 07, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription...
UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report
November 14, 2023 14:01 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication...
Repligen Corporation to Present at Upcoming Investor Conferences
November 07, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...
Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
November 02, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of...
Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
October 31, 2023 07:30 ET
|
Repligen Corporation
Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 millionOrders strengthened with total book-to-bill ratio of 1.07 Narrows full year revenue guidance to...
Repligen to Report Third Quarter 2023 Financial Results
October 17, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2023 financial results on Tuesday, October 31,...
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
October 02, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Announces Agreement to Acquire Fluid Management Innovator Metenova
September 26, 2023 07:30 ET
|
Repligen Corporation
Proposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applicationsExpands Repligen’s Fluid Management portfolio, complements single-use bag...
Repligen Appoints Jason K. Garland as Chief Financial Officer
September 12, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed...
Repligen Corporation to Present at Wells Fargo Healthcare Conference
September 01, 2023 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...